CX Institutional Acquires 13,959 Shares of Bristol Myers Squibb Company $BMY

CX Institutional boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 9.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 165,742 shares of the biopharmaceutical company’s stock after purchasing an additional 13,959 shares during the period. CX Institutional’s holdings in Bristol Myers Squibb were worth $7,475,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BMY. Norges Bank bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $1,554,154,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Bristol Myers Squibb by 428.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after purchasing an additional 9,171,098 shares in the last quarter. Man Group plc grew its holdings in shares of Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Bristol Myers Squibb by 142.8% during the 2nd quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after purchasing an additional 4,961,869 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY from Neutral to Buy and raised its price target to $65 (from $46), signaling stronger analyst conviction that BMY’s outlook and valuation are attractive — a clear near-term bullish catalyst for the stock. Bristol-Myers just upgraded at UBS — here’s why
• Positive Sentiment: Real‑world lung cancer data reported for nivolumab (Opdivo) adds evidence for continued demand in that indication, supporting BMY’s oncology revenue outlook and reducing execution risk around the immuno‑oncology franchise. Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story
• Positive Sentiment: BMS quietly opened a first‑in‑human study for BMS‑986521, expanding the pipeline and giving investors a new clinical readout to watch for longer‑term upside beyond legacy products. Quietly Expands Pipeline With New First-in-Human Study of BMS-986521
• Positive Sentiment: Analyst and media commentary (Zacks, Motley Fool) point to BMY’s history of earnings beats, attractive dividend yield and FY25 guidance (6.40–6.60 EPS), which supports expectations for another upside surprise. Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again Fat dividend and a chance for growth
• Neutral Sentiment: General market screens and sector stories (Zacks roundup pieces) include BMY as a medical stock to watch, but these are broader thematic notes rather than company‑specific catalysts. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Neutral Sentiment: Articles highlighting BMY’s strong return on equity and financial metrics provide context on quality but are not immediate price drivers. Is Bristol-Myers Squibb Company’s (NYSE:BMY) 33% ROE Better Than Average?
• Negative Sentiment: Valuation concerns tied to patent cliffs for Opdivo and Eliquis are being raised — some pieces argue current pricing may not fully reflect near‑term generic/competitive risk, which is a material downward pressure on longer‑term revenue forecasts if realized. Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks

Bristol Myers Squibb Stock Up 4.2%

Shares of BMY opened at $56.69 on Thursday. The business’s fifty day moving average price is $50.52 and its two-hundred day moving average price is $47.68. The firm has a market capitalization of $115.40 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 9.05 and a beta of 0.29. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a $0.63 dividend. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 85.14%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BMY. UBS Group upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the company from $46.00 to $65.00 in a research report on Wednesday. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Wells Fargo & Company increased their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Scotiabank restated a “sector perform” rating and set a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $56.08.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.